Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated June 2026
Most men starting TRT are handed a prescription for 200 mg of testosterone cypionate every two weeks and told to return in three months. That schedule is not a clinical decision. It is a habit inherited from the product labeling of an era when minimizing injection burden was the only consideration. It ignores what the pharmacokinetics actually do inside your body - and it explains why so many men in the ExcelMale community spend months feeling like they are on a hormonal rollercoaster when a simple protocol adjustment would fix it.
The question is not just how much testosterone to take. It is how to distribute it across time so that levels stay stable enough to feel consistently well, without hitting peaks high enough to cause side effects.
The answer is mechanical. Testosterone cypionate and enanthate are oil-based depot preparations. When you inject them, they do not enter the bloodstream immediately. They sit in the tissue and release testosterone through ester hydrolysis - the ester tail is cleaved, freeing active testosterone to absorb into circulation.
The problem with infrequent large doses is volume. A larger single injection creates a larger depot with a greater surface area, driving a rapid and aggressive influx of testosterone in the first few days. Pharmacokinetic studies show that a single 200 mg intramuscular dose of testosterone cypionate produces a three-fold rise in serum testosterone, with peak concentrations occurring around days 4-5 post-injection - levels that typically exceed the physiologic range. From there, levels decline steadily, often dropping back toward or below 300 ng/dL by day 14, which is where the next injection is scheduled.
The result is what clinicians call the sawtooth pattern. You are never in a steady replacement state. You alternate between pharmacological excess and near-deficiency every single cycle.
The sawtooth describes the shape of your serum testosterone curve when graphed over time with infrequent large injections. Early in the cycle, you may experience oily skin, acne, irritability, insomnia, or breast tenderness - these are peak effects, driven by the testosterone spike and the corresponding aromatization to estradiol. Late in the cycle, as the depot runs dry, fatigue returns, libido drops, brain fog appears, and morning erections disappear. These are trough effects.
The critical pharmacokinetic insight is that the amplitude of the sawtooth is directly proportional to the dose per injection. Larger doses at longer intervals produce more violent swings. Smaller doses at shorter intervals flatten the curve - and the flatter curve is achieved with the same total weekly testosterone amount. Population pharmacokinetic modeling of testosterone cypionate confirms that shifting from a single large infrequent injection to smaller more frequent doses reduces peak-to-trough ratios substantially.
Sex hormone-binding globulin is not just a diagnostic variable - it is the primary pharmacokinetic buffer for testosterone in your blood. SHBG binds a portion of circulating testosterone, holding it in reserve and slowing the rate at which free testosterone changes in response to rising or falling total levels.
Men with higher SHBG have a natural buffer that smooths the pharmacokinetic curve after each injection. Free testosterone rises more slowly and falls more slowly, which means they can tolerate longer intervals without the steep crash at the end of the cycle.
Men with low SHBG - frequently associated with obesity, insulin resistance, metabolic syndrome, or type 2 diabetes - have almost no buffer. When a testosterone bolus hits the blood, free testosterone spikes sharply. When the depot starts running out, free testosterone falls fast. For these men, even a weekly injection schedule often produces enough peak-to-trough variation to cause late-cycle symptoms. This is the primary reason SHBG has become, in the ExcelMale community and in progressive clinical practice, the arrow that points toward injection frequency.
These are starting points, not ceilings. The right frequency is ultimately determined by how your symptoms track your cycle. SHBG tells you where to start. Symptom stability tells you whether you have found the right schedule.
One additional consideration: low SHBG is frequently a marker of underlying metabolic dysfunction. Addressing obesity, insulin resistance, and fatty liver can raise SHBG naturally over time - which may in turn allow you to extend your injection interval and simplify your protocol.
This is the most important concept in individualized TRT management, and the one most often overlooked in primary care settings. When a man's symptoms return toward the end of his injection cycle, the default response in many clinics is to increase the total testosterone dose. This is usually the wrong answer.
If you are experiencing trough symptoms late in the cycle AND peak symptoms early in the cycle, the problem is the interval. Dose redistribution means taking the same total weekly amount and splitting it into smaller, more frequent injections. A man on 140 mg once weekly becomes a man on 70 mg twice weekly, or 20 mg daily. His total weekly testosterone is unchanged. What changes is the amplitude of the sawtooth.
Three things happen when you redistribute:
That last point matters especially. The "AI trap" - adding anastrozole to manage estradiol rather than correcting the injection schedule - is one of the most common management errors in TRT. Estradiol is not the enemy of male hormone health. A well-redistributed injection protocol often keeps estradiol in a healthy range without medication. Estradiol suppression below that range worsens libido, joint health, and bone density.
The practical threshold for redistribution is straightforward: if your symptoms reliably track your injection cycle - better in the first half, worse in the second - the interval is the primary problem. Escalating the dose without redistribution will amplify the peaks and worsen the same cycle you are trying to escape.
A serum testosterone number without timing context is a data point, not clinical information. The entire picture changes depending on when blood was drawn relative to the last injection.
Draw blood two days after a 200 mg injection and you may see 1,400 ng/dL. Draw the same blood on day 13 and you may see 280 ng/dL. A clinician looking at the 1,400 might cut your dose; one looking at the 280 might increase it. Both would be wrong without knowing the timing. This is the clinical trap that legacy biweekly dosing creates: the results look like overtreatment or undertreatment depending entirely on when the lab was ordered.
Every TRT lab requisition should document these items before the result is interpreted:
For men on stable protocols, drawing at trough - just before the next scheduled injection - provides the most reproducible baseline for comparison across lab visits. This gives you the lowest expected level and catches under-treatment directly. The caveat is that trough testing does not tell you how high your peaks are. If you are experiencing early-cycle side effects and your trough looks low, your prescriber may be tempted to raise the dose based on the trough result alone - without realizing that peak levels are already causing problems.
Frequency changes affect more than testosterone levels. Three physiological systems respond predictably to changes in peak exposure, and all three require monitoring when you adjust your protocol.
Testosterone stimulates red blood cell production by increasing erythropoietin and suppressing hepcidin, which raises iron availability for the bone marrow. High testosterone peaks - not the average weekly level - are the primary driver of this erythropoietic stimulus. Men on biweekly high-dose protocols are more likely to develop elevated hematocrit than men on more frequent smaller-dose protocols, even at the same total weekly dose.
If hematocrit exceeds 54%, current guidelines recommend reducing or temporarily stopping testosterone and reassessing the protocol. Bond et al. (2024) note that repeated phlebotomy without protocol correction addresses the symptom without fixing the mechanism. Before initiating phlebotomy, rule out other contributors: sleep apnea, chronic hypoxia, dehydration, smoking, and living at high altitude. Then evaluate whether more frequent smaller doses can stabilize hematocrit without phlebotomy.
Large testosterone peaks flood the aromatase enzyme, driving disproportionate estradiol production. Moving to more frequent smaller doses reduces peak substrate load and typically lowers the estradiol spike after each injection. Many men who shift to twice-weekly or daily protocols find their estradiol stabilizes within a healthy range without AI medication. If you are currently using anastrozole and you move to more frequent injections, monitor estradiol - you may need to taper or discontinue the AI to avoid over-suppression.
Blood pressure warrants monitoring for a different reason. Testosterone activates the renin-angiotensin-aldosterone system, influencing how the kidneys handle sodium and water. Rapid hormonal swings from infrequent large doses can trigger temporary sodium retention and blood pressure spikes in the 24-48 hours following injection. Men who notice blood pressure or weight increases after each injection should discuss protocol redistribution with their prescriber.
For most men with low SHBG (under 20 nmol/L), twice weekly is a reasonable starting point. Every other day becomes appropriate for men who still experience end-of-cycle symptoms on twice-weekly dosing, or who are using smaller total weekly doses where splitting into two injections produces very small volumes. Start at twice weekly, evaluate symptom stability across a full week, and increase frequency only if the late-cycle crash persists.
Not automatically. Redistribution means keeping the same weekly total and injecting it more often. Some men find that redistribution itself makes their current dose feel more effective - the higher average free testosterone at trough means they are getting more benefit from the same hormone. Others find that a modest dose reduction becomes possible once the protocol is optimized. Let labs at trough and symptom tracking guide that decision.
Yes, and this is one of the most practical reasons to consider the subcutaneous route for frequent protocols. A 27-29 gauge, half-inch insulin syringe makes daily or every-other-day injection far more tolerable than intramuscular injection at the same frequency. Research comparing subcutaneous testosterone enanthate to intramuscular testosterone cypionate (Choi et al., 2022) shows that subcutaneous delivery produces lower peak-to-trough ratios along with smaller increases in hematocrit and estradiol at equivalent doses. The smaller volumes used at higher frequency load easily into an insulin syringe, and most men find the technique straightforward to learn.
Daily injections are most appropriate for men who have tried twice-weekly or every-other-day dosing and still experience meaningful late-cycle symptoms, or for men with very low SHBG who process testosterone unusually rapidly. Daily dosing eliminates the sawtooth pattern almost entirely at the expense of injection burden. Subcutaneous delivery with a small insulin syringe makes daily injection far less disruptive than it sounds. Try every-other-day first. Evaluate for four to six weeks before deciding whether daily frequency adds meaningful benefit over that schedule.
Yes, usually favorably. Moving to more frequent smaller doses reduces the peak estradiol spike that follows each injection. Many men on twice-weekly or daily protocols find their estradiol stabilizes without AI medication. If you move to more frequent injections while already taking anastrozole, monitor estradiol closely - you may need to reduce or stop the AI to avoid crashing it. Treat estradiol symptoms, not laboratory numbers. Over-suppression of estradiol worsens libido, bone density, and joint health.
Start a symptom diary tied to your injection day. Rate your energy, libido, mood, and sleep quality on the day of injection, three days post-injection, and the day before your next dose. Do that for four weeks. If your ratings dip consistently in the second half of your cycle, you have identified a frequency problem. That data takes five minutes a week to collect and gives your prescribing clinician everything needed to make an intelligent protocol adjustment - without guesswork, and without another dose escalation that misses the point.
For deeper context on how SHBG affects free testosterone interpretation, see the SHBG Complete Guide on ExcelMale. If you are managing estradiol alongside frequency changes, the Anastrozole for Men guide covers the evidence on AI use in TRT in full.
Most men starting TRT are handed a prescription for 200 mg of testosterone cypionate every two weeks and told to return in three months. That schedule is not a clinical decision. It is a habit inherited from the product labeling of an era when minimizing injection burden was the only consideration. It ignores what the pharmacokinetics actually do inside your body - and it explains why so many men in the ExcelMale community spend months feeling like they are on a hormonal rollercoaster when a simple protocol adjustment would fix it.
The question is not just how much testosterone to take. It is how to distribute it across time so that levels stay stable enough to feel consistently well, without hitting peaks high enough to cause side effects.
Why Do You Feel Great Right After Your Injection, Then Crash Before the Next One?
The answer is mechanical. Testosterone cypionate and enanthate are oil-based depot preparations. When you inject them, they do not enter the bloodstream immediately. They sit in the tissue and release testosterone through ester hydrolysis - the ester tail is cleaved, freeing active testosterone to absorb into circulation.
The problem with infrequent large doses is volume. A larger single injection creates a larger depot with a greater surface area, driving a rapid and aggressive influx of testosterone in the first few days. Pharmacokinetic studies show that a single 200 mg intramuscular dose of testosterone cypionate produces a three-fold rise in serum testosterone, with peak concentrations occurring around days 4-5 post-injection - levels that typically exceed the physiologic range. From there, levels decline steadily, often dropping back toward or below 300 ng/dL by day 14, which is where the next injection is scheduled.
The result is what clinicians call the sawtooth pattern. You are never in a steady replacement state. You alternate between pharmacological excess and near-deficiency every single cycle.
What Is the Sawtooth Pattern, and Why Does Biweekly Dosing Create It?
The sawtooth describes the shape of your serum testosterone curve when graphed over time with infrequent large injections. Early in the cycle, you may experience oily skin, acne, irritability, insomnia, or breast tenderness - these are peak effects, driven by the testosterone spike and the corresponding aromatization to estradiol. Late in the cycle, as the depot runs dry, fatigue returns, libido drops, brain fog appears, and morning erections disappear. These are trough effects.
| Phase | Timing | Common Symptoms |
|---|---|---|
| Peak | Days 1-5 post-injection | Oily skin, acne, irritability, insomnia, breast tenderness, fluid retention |
| Trough | Days 10-14 (biweekly protocol) | Fatigue, low libido, brain fog, poor sleep, reduced morning erections, joint aches |
The critical pharmacokinetic insight is that the amplitude of the sawtooth is directly proportional to the dose per injection. Larger doses at longer intervals produce more violent swings. Smaller doses at shorter intervals flatten the curve - and the flatter curve is achieved with the same total weekly testosterone amount. Population pharmacokinetic modeling of testosterone cypionate confirms that shifting from a single large infrequent injection to smaller more frequent doses reduces peak-to-trough ratios substantially.
How Does Your SHBG Level Determine the Right Injection Frequency?
Sex hormone-binding globulin is not just a diagnostic variable - it is the primary pharmacokinetic buffer for testosterone in your blood. SHBG binds a portion of circulating testosterone, holding it in reserve and slowing the rate at which free testosterone changes in response to rising or falling total levels.
Men with higher SHBG have a natural buffer that smooths the pharmacokinetic curve after each injection. Free testosterone rises more slowly and falls more slowly, which means they can tolerate longer intervals without the steep crash at the end of the cycle.
Men with low SHBG - frequently associated with obesity, insulin resistance, metabolic syndrome, or type 2 diabetes - have almost no buffer. When a testosterone bolus hits the blood, free testosterone spikes sharply. When the depot starts running out, free testosterone falls fast. For these men, even a weekly injection schedule often produces enough peak-to-trough variation to cause late-cycle symptoms. This is the primary reason SHBG has become, in the ExcelMale community and in progressive clinical practice, the arrow that points toward injection frequency.
| SHBG Level | Pharmacokinetic Profile | Frequency Starting Point |
|---|---|---|
| Below 20 nmol/L (low) | Rapid free T fluctuation; sensitive to large boluses | Every other day or daily |
| 20-50 nmol/L (normal) | Moderate buffering; manages reasonable intervals | Twice weekly (most men) |
| Above 50 nmol/L (high) | Strong buffer; levels change slowly | Once weekly often sufficient |
These are starting points, not ceilings. The right frequency is ultimately determined by how your symptoms track your cycle. SHBG tells you where to start. Symptom stability tells you whether you have found the right schedule.
One additional consideration: low SHBG is frequently a marker of underlying metabolic dysfunction. Addressing obesity, insulin resistance, and fatty liver can raise SHBG naturally over time - which may in turn allow you to extend your injection interval and simplify your protocol.
What Is Dose Redistribution, and When Should You Try It Before Raising Your Dose?
This is the most important concept in individualized TRT management, and the one most often overlooked in primary care settings. When a man's symptoms return toward the end of his injection cycle, the default response in many clinics is to increase the total testosterone dose. This is usually the wrong answer.
If you are experiencing trough symptoms late in the cycle AND peak symptoms early in the cycle, the problem is the interval. Dose redistribution means taking the same total weekly amount and splitting it into smaller, more frequent injections. A man on 140 mg once weekly becomes a man on 70 mg twice weekly, or 20 mg daily. His total weekly testosterone is unchanged. What changes is the amplitude of the sawtooth.
Three things happen when you redistribute:
- Lower peaks. Smaller individual doses create a smaller depot, producing a gentler rise rather than a sharp spike. This alone often resolves early-cycle symptoms like acne, irritability, insomnia, and breast tenderness.
- Higher troughs. Because levels never fall as far before the next injection arrives, the late-cycle crash is softened or eliminated. Libido, energy, and morning erections remain more consistent across the week.
- More manageable aromatization. High testosterone peaks saturate the aromatase enzyme and drive disproportionate conversion to estradiol. Smaller more frequent doses reduce the peak substrate load, often reducing the estradiol spike enough to eliminate the need for aromatase inhibitor therapy.
That last point matters especially. The "AI trap" - adding anastrozole to manage estradiol rather than correcting the injection schedule - is one of the most common management errors in TRT. Estradiol is not the enemy of male hormone health. A well-redistributed injection protocol often keeps estradiol in a healthy range without medication. Estradiol suppression below that range worsens libido, joint health, and bone density.
The practical threshold for redistribution is straightforward: if your symptoms reliably track your injection cycle - better in the first half, worse in the second - the interval is the primary problem. Escalating the dose without redistribution will amplify the peaks and worsen the same cycle you are trying to escape.
Why Is Your Testosterone Lab Result Meaningless Without Injection Timing?
A serum testosterone number without timing context is a data point, not clinical information. The entire picture changes depending on when blood was drawn relative to the last injection.
Draw blood two days after a 200 mg injection and you may see 1,400 ng/dL. Draw the same blood on day 13 and you may see 280 ng/dL. A clinician looking at the 1,400 might cut your dose; one looking at the 280 might increase it. Both would be wrong without knowing the timing. This is the clinical trap that legacy biweekly dosing creates: the results look like overtreatment or undertreatment depending entirely on when the lab was ordered.
Every TRT lab requisition should document these items before the result is interpreted:
- Testosterone ester type and concentration (e.g., cypionate 200 mg/mL, enanthate 200 mg/mL)
- Dose per injection in milligrams - not milliliters, which vary by product concentration
- Route of administration (intramuscular or subcutaneous)
- Date and time of the last injection
- Date and time of the blood draw
For men on stable protocols, drawing at trough - just before the next scheduled injection - provides the most reproducible baseline for comparison across lab visits. This gives you the lowest expected level and catches under-treatment directly. The caveat is that trough testing does not tell you how high your peaks are. If you are experiencing early-cycle side effects and your trough looks low, your prescriber may be tempted to raise the dose based on the trough result alone - without realizing that peak levels are already causing problems.
What Safety Markers Should You Monitor When Adjusting Injection Frequency?
Frequency changes affect more than testosterone levels. Three physiological systems respond predictably to changes in peak exposure, and all three require monitoring when you adjust your protocol.
How Does Injection Frequency Affect Hematocrit?
Testosterone stimulates red blood cell production by increasing erythropoietin and suppressing hepcidin, which raises iron availability for the bone marrow. High testosterone peaks - not the average weekly level - are the primary driver of this erythropoietic stimulus. Men on biweekly high-dose protocols are more likely to develop elevated hematocrit than men on more frequent smaller-dose protocols, even at the same total weekly dose.
If hematocrit exceeds 54%, current guidelines recommend reducing or temporarily stopping testosterone and reassessing the protocol. Bond et al. (2024) note that repeated phlebotomy without protocol correction addresses the symptom without fixing the mechanism. Before initiating phlebotomy, rule out other contributors: sleep apnea, chronic hypoxia, dehydration, smoking, and living at high altitude. Then evaluate whether more frequent smaller doses can stabilize hematocrit without phlebotomy.
What Should I Monitor for Estradiol and Blood Pressure on TRT?
Large testosterone peaks flood the aromatase enzyme, driving disproportionate estradiol production. Moving to more frequent smaller doses reduces peak substrate load and typically lowers the estradiol spike after each injection. Many men who shift to twice-weekly or daily protocols find their estradiol stabilizes within a healthy range without AI medication. If you are currently using anastrozole and you move to more frequent injections, monitor estradiol - you may need to taper or discontinue the AI to avoid over-suppression.
Blood pressure warrants monitoring for a different reason. Testosterone activates the renin-angiotensin-aldosterone system, influencing how the kidneys handle sodium and water. Rapid hormonal swings from infrequent large doses can trigger temporary sodium retention and blood pressure spikes in the 24-48 hours following injection. Men who notice blood pressure or weight increases after each injection should discuss protocol redistribution with their prescriber.
| Safety Marker | What to Watch | Action Threshold |
|---|---|---|
| Hematocrit | Red blood cell concentration; rises with testosterone peaks | Above 54% - review frequency and dose before phlebotomy |
| Estradiol (E2) | Aromatization of testosterone; rises with large peaks | Treat symptoms, not numbers; redistribute dose before adding AI |
| Blood pressure | RAAS activation; fluid retention with peak spikes | Monitor post-injection; redistribution often stabilizes BP |
| LH / FSH | Will be suppressed on TRT regardless of frequency | Confirm suppression is expected; relevant for fertility planning |
Frequently Asked Questions
Is Twice Weekly or Every Other Day Better for Low SHBG?
For most men with low SHBG (under 20 nmol/L), twice weekly is a reasonable starting point. Every other day becomes appropriate for men who still experience end-of-cycle symptoms on twice-weekly dosing, or who are using smaller total weekly doses where splitting into two injections produces very small volumes. Start at twice weekly, evaluate symptom stability across a full week, and increase frequency only if the late-cycle crash persists.
Does More Frequent Injection Mean a Lower Total Dose?
Not automatically. Redistribution means keeping the same weekly total and injecting it more often. Some men find that redistribution itself makes their current dose feel more effective - the higher average free testosterone at trough means they are getting more benefit from the same hormone. Others find that a modest dose reduction becomes possible once the protocol is optimized. Let labs at trough and symptom tracking guide that decision.
Can Switching to Subcutaneous Injections Help with Frequency Changes?
Yes, and this is one of the most practical reasons to consider the subcutaneous route for frequent protocols. A 27-29 gauge, half-inch insulin syringe makes daily or every-other-day injection far more tolerable than intramuscular injection at the same frequency. Research comparing subcutaneous testosterone enanthate to intramuscular testosterone cypionate (Choi et al., 2022) shows that subcutaneous delivery produces lower peak-to-trough ratios along with smaller increases in hematocrit and estradiol at equivalent doses. The smaller volumes used at higher frequency load easily into an insulin syringe, and most men find the technique straightforward to learn.
At What Point Should I Consider Daily Injections?
Daily injections are most appropriate for men who have tried twice-weekly or every-other-day dosing and still experience meaningful late-cycle symptoms, or for men with very low SHBG who process testosterone unusually rapidly. Daily dosing eliminates the sawtooth pattern almost entirely at the expense of injection burden. Subcutaneous delivery with a small insulin syringe makes daily injection far less disruptive than it sounds. Try every-other-day first. Evaluate for four to six weeks before deciding whether daily frequency adds meaningful benefit over that schedule.
Will Changing Injection Frequency Affect My Estradiol or Need for an AI?
Yes, usually favorably. Moving to more frequent smaller doses reduces the peak estradiol spike that follows each injection. Many men on twice-weekly or daily protocols find their estradiol stabilizes without AI medication. If you move to more frequent injections while already taking anastrozole, monitor estradiol closely - you may need to reduce or stop the AI to avoid crashing it. Treat estradiol symptoms, not laboratory numbers. Over-suppression of estradiol worsens libido, bone density, and joint health.
Conclusion: One Practical Step You Can Take This Week
Start a symptom diary tied to your injection day. Rate your energy, libido, mood, and sleep quality on the day of injection, three days post-injection, and the day before your next dose. Do that for four weeks. If your ratings dip consistently in the second half of your cycle, you have identified a frequency problem. That data takes five minutes a week to collect and gives your prescribing clinician everything needed to make an intelligent protocol adjustment - without guesswork, and without another dose escalation that misses the point.
For deeper context on how SHBG affects free testosterone interpretation, see the SHBG Complete Guide on ExcelMale. If you are managing estradiol alongside frequency changes, the Anastrozole for Men guide covers the evidence on AI use in TRT in full.
Related ExcelMale Forum Discussions
- What's the Ideal Interval Between TRT Injections? - Community thread where SHBG emerges as the decisive variable for choosing weekly, twice-weekly, or daily schedules.
- Testosterone Injection Frequency and Its Effect on Hematocrit - Member experiences with how switching injection frequency affected red blood cell counts, with some counterintuitive findings.
- When to Test for Peak or Trough - Covers the exact post-injection timing of peak and trough levels for cypionate and enanthate, and why testing without that context misrepresents your results.
- Does Testosterone Cypionate Really Trough After 3.5 Days? - Real member lab data comparing peak and trough serum levels on twice-weekly cypionate protocols, including EOD observations.
- Peak vs. Trough Levels: Member Data and Calculations - Community calculations and blood work comparisons explaining the expected ratio between peak and trough on different injection intervals.
- Injection Frequency Effect on SHBG - Does changing how often you inject actually change your SHBG levels? Community discussion and research evidence.
- SHBG: The Complete Guide for Men on TRT - Nelson Vergel's comprehensive ExcelMale article covering how SHBG is measured, what drives it up or down, and how it shapes free testosterone across different TRT protocols.
- Anastrozole for Men: The Complete Evidence-Based Guide - Evidence review covering when aromatase inhibitors are and are not appropriate in TRT, including why dose redistribution should be tried first for estradiol management.
- IM vs. Subcutaneous Testosterone Injections: Which Is Right for You? - Practical guide to subcutaneous injection technique for men using frequent dosing protocols, including needle size, site selection, and volume considerations.
- Injection Frequency Discussion Hub - The ExcelMale tag page aggregating the most active member discussions on EOD, daily, twice-weekly, and weekly injection schedules across different doses and esters.
Key References
- Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril. 1987;47(6):1004-9. DOI
- Bi Y, et al. Population pharmacokinetic/pharmacodynamic modeling of depot testosterone cypionate in healthy male subjects. CPT Pharmacometrics Syst Pharmacol. 2018;7(10):654-663. DOI
- Choi EJ, Xu P, Barham D, et al. Comparison of outcomes for hypogonadal men treated with intramuscular testosterone cypionate versus subcutaneous testosterone enanthate. J Urol. 2022;207(3):677-683. DOI
- Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector: a phase II study. Sex Med. 2015;3(4):269-79. DOI
- Pastuszak AW, et al. Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology. 2022;10(7):1324-1339. DOI
- Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocr Connect. 2024;13(10):e240283. DOI
- Agrawal P, Singh SM, Kohn TP. Management of erythrocytosis in men receiving testosterone therapy: clinical consultation guide. Eur Urol Focus. 2023;9(1):20-21. DOI
- Walia A, et al. Testosterone replacement, where are we in 2025? Trends Urol Mens Health. 2025. DOI
Last edited:
